Cryoport’s (CYRX) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Cryoport (NASDAQ:CYRX) in a report released on Wednesday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other research firms have also recently issued reports on CYRX. UBS Group increased their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a research report on Thursday, April 10th. Finally, Roth Mkm restated a “buy” rating and issued a $15.00 price objective on shares of Cryoport in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Cryoport has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Cryoport Stock Down 1.1 %

Shares of Cryoport stock opened at $5.55 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport has a 1-year low of $4.58 and a 1-year high of $17.41. The business’s fifty day moving average price is $5.99 and its two-hundred day moving average price is $7.02. The company has a market capitalization of $277.00 million, a P/E ratio of -1.64 and a beta of 1.81.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. As a group, research analysts forecast that Cryoport will post -0.99 EPS for the current year.

Insider Activity

In related news, CEO Jerrell Shelton sold 4,620 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at approximately $4,814,359.71. The trade was a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 19,830 shares of company stock worth $118,353 over the last quarter. Corporate insiders own 10.10% of the company’s stock.

Institutional Trading of Cryoport

Several large investors have recently added to or reduced their stakes in CYRX. Point72 Asia Singapore Pte. Ltd. lifted its holdings in Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Cryoport in the fourth quarter valued at approximately $51,000. Avanza Fonder AB bought a new stake in shares of Cryoport during the 4th quarter worth $64,000. Quarry LP acquired a new position in Cryoport in the 4th quarter valued at $69,000. Finally, GAMMA Investing LLC raised its holdings in Cryoport by 4,434.6% in the 1st quarter. GAMMA Investing LLC now owns 14,556 shares of the company’s stock worth $89,000 after acquiring an additional 14,235 shares during the period. 92.90% of the stock is owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.